Valuation: Corbus Pharmaceuticals Holdings, Inc.

Market Cap 80.27M 72.04M 66.52M 60.32M 113M 7.62B 114M 797M 317M 4B 301M 295M 12.67B P/E 2026 *
-0.76x
P/E 2027 * -0.72x
Enterprise Value 80.27M 72.04M 66.52M 60.32M 113M 7.62B 114M 797M 317M 4B 301M 295M 12.67B EV / Sales 2026 *
72.2x
EV / Sales 2027 * 33.4x
Free-Float
98.76%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Corbus Pharmaceuticals Holdings, Inc.

1 day+4.01%
1 week-6.11%
Current month-39.15%
1 month-41.88%
3 months-54.30%
6 months-58.83%
Current year-49.02%
1 week 3.87
Extreme 3.87
4.52
1 month 3.87
Extreme 3.87
7.05
Current year 3.87
Extreme 3.87
12.88
1 year 3.87
Extreme 3.87
17.75
3 years 3.03
Extreme 3.0334
61.9
5 years 2.11
Extreme 2.11
61.9
10 years 2.11
Extreme 2.11
315
Manager TitleAgeSince
Chief Executive Officer 51 11/04/2014
Director of Finance/CFO 68 11/04/2014
Chief Tech/Sci/R&D Officer 48 06/07/2026
Director TitleAgeSince
Director/Board Member 51 11/04/2014
Director/Board Member 68 05/06/2018
Chairman 54 15/05/2025
Date Insider Type Main position Quantity % Market Cap. Importance
14/09/26 Sell

Director

-2,000 0.0103%
16/08/26 Free

Chief Technology Officer

250,009 1.3494%
11/08/26 Buy

Executive/Senior Manager

2,600 0.0140%
Change 5-day change 1-year change 3-year change Capi.($)
+4.01%-6.11%-75.60%-20.35% 80.27M
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.33%+0.33%+10.16%+78.07% 54.55B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+1.11%+15.18%+60.27%+49.33% 26.7B
+3.54%-6.40%+25.79%-8.44% 23.36B
Average +0.45%-1.68%+33.62%+137.11% 38.05B
Weighted average by Cap. -0.31%-1.27%+42.91%+155.25%

Financials

2026 *2027 *
Net sales 1.11M 997K 921K 835K 1.56M 106M 1.58M 11.04M 4.38M 55.32M 4.17M 4.08M 175M 2.4M 2.15M 1.99M 1.8M 3.37M 228M 3.41M 23.85M 9.47M 119M 9.01M 8.82M 379M
Net income -116M -104M -96.35M -87.37M -163M -11.04B -165M -1.16B -459M -5.79B -436M -427M -18.36B -135M -121M -112M -102M -190M -12.84B -192M -1.34B -533M -6.73B -507M -496M -21.34B
Net Debt - -
Projected Income Statement - Annual - Corbus Pharmaceuticals Holdings, Inc.
Logo Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company. The Company has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.
Employees
36
Date Price Change Volume
27/10/26 $4.150 +4.01% 716,710
26/10/26 $3.990 -1.48% 847,373
23/10/26 $4.050 -1.94% 372,924
22/10/26 $4.130 -3.62% 983,758
21/10/26 $4.285 -3.05% 625,935
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Corbus Pharmaceuticals Holdings, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.150USD
Average target price
35.89USD
Spread / Average Target
+764.79%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Corbus Pharmaceuticals Holdings, Inc.
  1. Stock Market
  2. Stocks
  3. CRBP Stock